MedTrace Logo

Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine

NCT03914053 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3387

Last updated 2019-04-12

No results posted yet for this study

Summary

Despite the rise in prescriptions for direct oral anticoagulants,Vitamin K antagonists(VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.

Conditions

  • Thromboembolism

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Emile Emile · University Hospital, Montpellier

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2018-09-01
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914053 on ClinicalTrials.gov